A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study
ClinicalTrials.gov ID: NCT01194830
Organization: Boehringer Ingelheim
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: PHASE3
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: Linagliptin
DRUG: Placebo
Lead sponsor: Boehringer Ingelheim (INDUSTRY)
Collaborators: Eli Lilly and Company
Enrollment: 234 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 80 Years
Accepts healthy volunteers: no
Start date: 2010-09
Completion date: 2011-10
Locations:
facility: 1218.75.059 Boehringer Ingelheim Investigational Site
city: Birmingham
state: Alabama
country: United States
facility: 1218.75.054 Boehringer Ingelheim Investigational Site
city: Huntsville
state: Alabama
country: United States
facility: 1218.75.035 Boehringer Ingelheim Investigational Site
city: Mobile
state: Alabama
country: United States
facility: 1218.75.101 Boehringer Ingelheim Investigational Site
city: Toney
state: Alabama
country: United States
facility: 1218.75.066 Boehringer Ingelheim Investigational Site
city: Little Rock
state: Alaska
country: United States
facility: 1218.75.008 Boehringer Ingelheim Investigational Site
city: Pell City
state: Alaska
country: United States
facility: 1218.75.071 Boehringer Ingelheim Investigational Site
city: Anaheim
state: California
country: United States
facility: 1218.75.018 Boehringer Ingelheim Investigational Site
city: Chino
state: California
country: United States
facility: 1218.75.081 Boehringer Ingelheim Investigational Site
city: Garden Grove
state: California
country: United States
facility: 1218.75.109 Boehringer Ingelheim Investigational Site
city: Los Angeles
state: California
country: United States
facility: 1218.75.040 Boehringer Ingelheim Investigational Site
city: Colorado Springs
state: Colorado
country: United States
facility: 1218.75.047 Boehringer Ingelheim Investigational Site
city: Denver
state: Colorado
country: United States
facility: 1218.75.106 Boehringer Ingelheim Investigational Site
city: Bartow
state: Florida
country: United States
facility: 1218.75.098 Boehringer Ingelheim Investigational Site
city: Bradenton
state: Florida
country: United States
facility: 1218.75.036 Boehringer Ingelheim Investigational Site
city: Chiefland
state: Florida
country: United States
facility: 1218.75.105 Boehringer Ingelheim Investigational Site
city: Fort Lauderdale
state: Florida
country: United States
facility: 1218.75.083 Boehringer Ingelheim Investigational Site
city: Fort Myers
state: Florida
country: United States
facility: 1218.75.002 Boehringer Ingelheim Investigational Site
city: Hialeah
state: Florida
country: United States
facility: 1218.75.080 Boehringer Ingelheim Investigational Site
city: Jacksonville
state: Florida
country: United States
facility: 1218.75.065 Boehringer Ingelheim Investigational Site
city: Jupiter
state: Florida
country: United States
facility: 1218.75.007 Boehringer Ingelheim Investigational Site
city: Miami
state: Florida
country: United States
facility: 1218.75.029 Boehringer Ingelheim Investigational Site
city: Miami
state: Florida
country: United States
facility: 1218.75.045 Boehringer Ingelheim Investigational Site
city: Miami
state: Florida
country: United States
facility: 1218.75.084 Boehringer Ingelheim Investigational Site
city: Miami
state: Florida
country: United States
facility: 1218.75.017 Boehringer Ingelheim Investigational Site
city: Ocala
state: Florida
country: United States
facility: 1218.75.012 Boehringer Ingelheim Investigational Site
city: Pinellas Park
state: Florida
country: United States
facility: 1218.75.074 Boehringer Ingelheim Investigational Site
city: Port Orange
state: Florida
country: United States
facility: 1218.75.076 Boehringer Ingelheim Investigational Site
city: South Miami
state: Florida
country: United States
facility: 1218.75.003 Boehringer Ingelheim Investigational Site
city: St. Petersburg
state: Florida
country: United States
facility: 1218.75.039 Boehringer Ingelheim Investigational Site
city: St. Petersburg
state: Florida
country: United States
facility: 1218.75.075 Boehringer Ingelheim Investigational Site
city: Tallahassee
state: Florida
country: United States
facility: 1218.75.100 Boehringer Ingelheim Investigational Site
city: Tamarac
state: Florida
country: United States
facility: 1218.75.015 Boehringer Ingelheim Investigational Site
city: Tampa
state: Florida
country: United States
facility: 1218.75.103 Boehringer Ingelheim Investigational Site
city: West Palm Beach
state: Florida
country: United States
facility: 1218.75.049 Boehringer Ingelheim Investigational Site
city: Atlanta
state: Georgia
country: United States
facility: 1218.75.067 Boehringer Ingelheim Investigational Site
city: Calhoun
state: Georgia
country: United States
facility: 1218.75.016 Boehringer Ingelheim Investigational Site
city: Dunwoody
state: Georgia
country: United States
facility: 1218.75.063 Boehringer Ingelheim Investigational Site
city: Lawrenceville
state: Georgia
country: United States
facility: 1218.75.056 Boehringer Ingelheim Investigational Site
city: Marietta
state: Georgia
country: United States
facility: 1218.75.026 Boehringer Ingelheim Investigational Site
city: Rosswell
state: Georgia
country: United States
facility: 1218.75.079 Boehringer Ingelheim Investigational Site
city: Sandy Springs
state: Georgia
country: United States
facility: 1218.75.034 Boehringer Ingelheim Investigational Site
city: Snellville
state: Georgia
country: United States
facility: 1218.75.001 Boehringer Ingelheim Investigational Site
city: Chicago
state: Illinois
country: United States
facility: 1218.75.055 Boehringer Ingelheim Investigational Site
city: Chicago
state: Illinois
country: United States
facility: 1218.75.069 Boehringer Ingelheim Investigational Site
city: Owensboro
state: Kentucky
country: United States
facility: 1218.75.044 Boehringer Ingelheim Investigational Site
city: Baton Rouge
state: Louisiana
country: United States
facility: 1218.75.108 Boehringer Ingelheim Investigational Site
city: Essex
state: Maryland
country: United States
facility: 1218.75.086 Boehringer Ingelheim Investigational Site
city: Brockton
state: Massachusetts
country: United States
facility: 1218.75.087 Boehringer Ingelheim Investigational Site
city: Watertown
state: Massachusetts
country: United States
facility: 1218.75.051 Boehringer Ingelheim Investigational Site
city: Detroit
state: Michigan
country: United States
facility: 1218.75.088 Boehringer Ingelheim Investigational Site
city: Flint
state: Michigan
country: United States
facility: 1218.75.099 Boehringer Ingelheim Investigational Site
city: Biloxi
state: Mississippi
country: United States
facility: 1218.75.006 Boehringer Ingelheim Investigational Site
city: Atco
state: New Jersey
country: United States
facility: 1218.75.004 Boehringer Ingelheim Investigational Site
city: Camden
state: New Jersey
country: United States
facility: 1218.75.031 Boehringer Ingelheim Investigational Site
city: Brooklyn
state: New York
country: United States
facility: 1218.75.095 Boehringer Ingelheim Investigational Site
city: Brooklyn
state: New York
country: United States
facility: 1218.75.038 Boehringer Ingelheim Investigational Site
city: Asheboro
state: North Carolina
country: United States
facility: 1218.75.009 Boehringer Ingelheim Investigational Site
city: Charlotte
state: North Carolina
country: United States
facility: 1218.75.023 Boehringer Ingelheim Investigational Site
city: Charlotte
state: North Carolina
country: United States
facility: 1218.75.060 Boehringer Ingelheim Investigational Site
city: Charlotte
state: North Carolina
country: United States
facility: 1218.75.005 Boehringer Ingelheim Investigational Site
city: Greensboro
state: North Carolina
country: United States
facility: 1218.75.107 Boehringer Ingelheim Investigational Site
city: High Point
state: North Carolina
country: United States
facility: 1218.75.020 Boehringer Ingelheim Investigational Site
city: Jacksonville
state: North Carolina
country: United States
facility: 1218.75.027 Boehringer Ingelheim Investigational Site
city: Winston-Salem
state: North Carolina
country: United States
facility: 1218.75.096 Boehringer Ingelheim Investigational Site
city: Akron
state: Ohio
country: United States
facility: 1218.75.090 Boehringer Ingelheim Investigational Site
city: Columbus
state: Ohio
country: United States
facility: 1218.75.078 Boehringer Ingelheim Investigational Site
city: Dayton
state: Ohio
country: United States
facility: 1218.75.037 Boehringer Ingelheim Investigational Site
city: Philadelphia
state: Pennsylvania
country: United States
facility: 1218.75.082 Boehringer Ingelheim Investigational Site
city: Philadelphia
state: Pennsylvania
country: United States
facility: 1218.75.010 Boehringer Ingelheim Investigational Site
city: Uniontown
state: Pennsylvania
country: United States
facility: 1218.75.028 Boehringer Ingelheim Investigational Site
city: Uniontown
state: Pennsylvania
country: United States
facility: 1218.75.091 Boehringer Ingelheim Investigational Site
city: Anderson
state: South Carolina
country: United States
facility: 1218.75.072 Boehringer Ingelheim Investigational Site
city: Columbia
state: South Carolina
country: United States
facility: 1218.75.068 Boehringer Ingelheim Investigational Site
city: Greenwood
state: South Carolina
country: United States
facility: 1218.75.097 Boehringer Ingelheim Investigational Site
city: Greer
state: South Carolina
country: United States
facility: 1218.75.024 Boehringer Ingelheim Investigational Site
city: Brentwood
state: Tennessee
country: United States
facility: 1218.75.025 Boehringer Ingelheim Investigational Site
city: Collierville
state: Tennessee
country: United States
facility: 1218.75.011 Boehringer Ingelheim Investigational Site
city: Germantown
state: Tennessee
country: United States
facility: 1218.75.042 Boehringer Ingelheim Investigational Site
city: Humboldt
state: Tennessee
country: United States
facility: 1218.75.030 Boehringer Ingelheim Investigational Site
city: Memphis
state: Tennessee
country: United States
facility: 1218.75.050 Boehringer Ingelheim Investigational Site
city: Memphis
state: Tennessee
country: United States
facility: 1218.75.053 Boehringer Ingelheim Investigational Site
city: Dallas
state: Texas
country: United States
facility: 1218.75.057 Boehringer Ingelheim Investigational Site
city: Houston
state: Texas
country: United States
facility: 1218.75.064 Boehringer Ingelheim Investigational Site
city: Houston
state: Texas
country: United States
facility: 1218.75.104 Boehringer Ingelheim Investigational Site
city: Houston
state: Texas
country: United States
facility: 1218.75.043 Boehringer Ingelheim Investigational Site
city: Houton
state: Texas
country: United States
facility: 1218.75.022 Boehringer Ingelheim Investigational Site
city: San Antonio
state: Texas
country: United States
facility: 1218.75.058 Boehringer Ingelheim Investigational Site
city: Sugar Land
state: Texas
country: United States
facility: 1218.75.033 Boehringer Ingelheim Investigational Site
city: Tomball
state: Texas
country: United States
facility: 1218.75.102 Boehringer Ingelheim Investigational Site
city: Tomball
state: Texas
country: United States
facility: 1218.75.094 Boehringer Ingelheim Investigational Site
city: Waco
state: Texas
country: United States
facility: 1218.75.092 Boehringer Ingelheim Investigational Site
city: Whitney
state: Texas
country: United States
facility: 1218.75.019 Boehringer Ingelheim Investigational Site
city: Virgnia Beach
state: Virginia
country: United States

Summary:
Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study